GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Now Rated "Hold" by Sell-Side Analysts

Key Points

• GoodRx carries a consensus “Hold” rating among 13 analysts: three recommend selling, six advise holding, and four recommend buying. The average 12-month price target is $4.23.
• GoodRx reported quarterly earnings of $0.08 per share, in line with estimates, while revenue of $200.41 million exceeded expectations. However, revenue declined 1.3% year over year.
• The stock opened at $3.48, with a market capitalization of approximately $1.19 billion. Insiders sold 2.76 million shares worth about $9.67 million over the past 90 days, while institutional investors own 63.77% of outstanding shares.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been assigned a consensus rating of "Hold" from the thirteen analysts that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $4.23.

GDRX has been the topic of several recent research reports. The Goldman Sachs Group restated a "neutral" rating and set a $4.00 target price on shares of GoodRx in a report on Friday, August 7th. Citigroup increased their price target on GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. TD Cowen raised their price objective on GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Barclays raised their price objective on GoodRx from $3.00 to $4.00 and gave the company an "underweight" rating in a research report on Thursday, August 20th. Finally, Wells Fargo & Company boosted their price objective on GoodRx from $3.50 to $5.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th.

GoodRx Stock Performance

GDRX opened at $3.48 on Wednesday. GoodRx has a 1 year low of $1.77 and a 1 year high of $3.89. The firm has a 50 day moving average price of $3.44 and a 200 day moving average price of $2.81. The company has a market cap of $1.19 billion, a PE ratio of 87.02 and a beta of 1.69.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting analysts' consensus estimates of $0.08. The business had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. During the same period last year, the firm earned $0.09 earnings per share. The company's quarterly revenue was down 1.3% on a year-over-year basis. On average, sell-side analysts predict that GoodRx will post 0.16 earnings per share for the current year.

Insider Activity

In related news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 2,760,995 shares of company stock valued at $9,673,207 in the last ninety days. 5.87% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GoodRx

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Essential Partners LLC raised its stake in shares of GoodRx by 375.4% during the first quarter. Essential Partners LLC now owns 14,304 shares of the company's stock valued at $28,000 after purchasing an additional 11,295 shares during the period. SG Americas Securities LLC acquired a new position in shares of GoodRx during the first quarter worth $29,000. Headlands Technologies LLC purchased a new position in shares of GoodRx in the second quarter valued at $30,000. Krilogy Financial LLC purchased a new position in shares of GoodRx in the first quarter valued at $33,000. Finally, Amundi purchased a new position in shares of GoodRx in the first quarter valued at $37,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc operates a digital healthcare platform that helps consumers find and access lower prices for prescription medications. Through its website and mobile applications, GoodRx allows users to compare prices at participating pharmacies, obtain prescription discount coupons and identify potential savings on commonly prescribed drugs. The company's services are generally available at pharmacies across the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as healthcare-related content and tools designed to help consumers understand medications and treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.